R406SYK inhibitor,potent and ATP-competitive CAS# 841290-81-1 |
- Piceatannol
Catalog No.:BCN5824
CAS No.:10083-24-6
- MNS
Catalog No.:BCC3943
CAS No.:1485-00-3
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 841290-81-1 | SDF | Download SDF |
PubChem ID | 11984591 | Appearance | Powder |
Formula | C28H29FN6O8S | M.Wt | 628.63 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : ≥ 61 mg/mL (97.04 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | benzenesulfonic acid;6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one | ||
SMILES | CC1(C(=O)NC2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)C.C1=CC=C(C=C1)S(=O)(=O)O | ||
Standard InChIKey | UXDRJPYSTZHIOE-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C22H23FN6O5.C6H6O3S/c1-22(2)20(30)28-19-13(34-22)6-7-16(27-19)26-18-12(23)10-24-21(29-18)25-11-8-14(31-3)17(33-5)15(9-11)32-4;7-10(8,9)6-4-2-1-3-5-6/h6-10H,1-5H3,(H3,24,25,26,27,28,29,30);1-5H,(H,7,8,9) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | R406 is a potent inhibitor of Syk with IC50 of 41 nM. | |||||
Targets | Syk | |||||
IC50 | 41 nM |
Cell experiment: [1] | |
Cell lines | Human mast cells |
Preparation method | The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months. |
Reacting condition | EC50: 56 nM, 30min |
Applications | Cells were incubated with R406 or DMSO for 30 min. They were then stimulated with either 0.25 to 2 mg/ml anti-IgE or anti-IgG or 2 μM ionomycin. R406 dose-dependently inhibited anti-IgE-mediated CHMC degranulation measured as tryptase release but showed no activity on ionomycin-triggered tryptase release, indicating that R406 is specific to FcR signaling and not degranulation per se. As intended, this specific inhibition also implies that R406 site of action is proximal to the receptor complex and upstream of calcium mobilization. |
Animal experiment: [1] | |
Animal models | Female C57BL/6 mice |
Dosage form | Oral administration, 0.1, 0.5, 1 and 5 mg.kg |
Application | Mice were used for the model of immune complex - mediated inflammation. The ability of R406 to inhibit the reverse passive Arthus reaction was investigated in this model. Prophylactic treatment of mice with R406 administered 1 h before immune complex challenge reduced the cutaneous reverse passive Arthus reaction by approximately 72 and 86% at 1 and 5 mg/kg, respectively, compared with the vehicle control. The net optical density reading of extravasated dye extracted after treatment with R406 at 1 or 5 mg/kg R406 was reduced from 0.14 (vehicle) to 0.04 or 0.02, respectively. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1] Braselmann S, Taylor V, Zhao H, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. Journal of Pharmacology and Experimental Therapeutics, 2006, 319(3): 998-1008. |
R406 Dilution Calculator
R406 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.5908 mL | 7.9538 mL | 15.9076 mL | 31.8152 mL | 39.769 mL |
5 mM | 0.3182 mL | 1.5908 mL | 3.1815 mL | 6.363 mL | 7.9538 mL |
10 mM | 0.1591 mL | 0.7954 mL | 1.5908 mL | 3.1815 mL | 3.9769 mL |
50 mM | 0.0318 mL | 0.1591 mL | 0.3182 mL | 0.6363 mL | 0.7954 mL |
100 mM | 0.0159 mL | 0.0795 mL | 0.1591 mL | 0.3182 mL | 0.3977 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins. It is crucial for adaptive immune response, and also very important for cellular adhesion, innate immune recognition, osteoclast maturation, platelet activation and vascular development. [1]
Functional abnormality of SYK has been implicated in several blood malignancies. Constitutively active SYK can transform B cells. SYK inhibition can be beneficial for patients with blood cancers and autoimmune diseases.
R406 is a potent inhibitor of IgE and IgG mediated Fc receptor activation with EC50 for degranulation of 56-64 nM. [2] R406 targets SYK and inhibits phosphorylation of SYK substrates by binding to its ATP binding pocket and competing with ATP. R406 strongly inhibits SYK kinase activity with an IC50 of 41 nM.
R406 induces apoptosis in diffuse large B-cell lymphoma cell lines. It blocks B cell receptor signaling through inhibiton of SYK autophosphorylation of Y525/Y526 and SYK-dependent phosphorylation of the B-cell linker protein. [3]
R406 can be administrated orally.
References:
[1]Mocsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol 2010. 10(6): 387-402.
[2]Braselmann S, Taylor V, Zhao H, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 2006. 319(3): 998-1008.
[3]Chen L, Monti S, Juszczynski P, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 2008. 111(4): 2230*2237.
- R406 (free base)
Catalog No.:BCC2553
CAS No.:841290-80-0
- Triptotriterpenic acid A
Catalog No.:BCN6780
CAS No.:84108-17-8
- Wilforlide A acetate
Catalog No.:BCN4384
CAS No.:84104-80-3
- Wilforlide A
Catalog No.:BCN4383
CAS No.:84104-71-2
- 1-Benzhydrylpiperazine
Catalog No.:BCC8453
CAS No.:841-77-0
- Roquinimex
Catalog No.:BCC5355
CAS No.:84088-42-6
- Lamotrigine
Catalog No.:BCC5051
CAS No.:84057-84-1
- Helioxanthin 8-1
Catalog No.:BCC5415
CAS No.:840529-13-7
- Fmoc-N-Me-Val-OH
Catalog No.:BCC3358
CAS No.:84000-11-3
- Fmoc-N-Me-Ala-OH
Catalog No.:BCC3210
CAS No.:84000-07-7
- Xanthoxyletin
Catalog No.:BCN6579
CAS No.:84-99-1
- Vitamin K1
Catalog No.:BCN2209
CAS No.:84-80-0
- 6-Fluoro-3-(4-piperidinyl)-1,2-benzisoxazole hydrochloride
Catalog No.:BCC8772
CAS No.:84163-13-3
- Ac-Glu(OtBu)-OH
Catalog No.:BCC2921
CAS No.:84192-88-1
- 7 8-Dihydroxy-4-Phenylcoumarin
Catalog No.:BCC8289
CAS No.:842-01-3
- Sudan I
Catalog No.:BCN8378
CAS No.:842-07-9
- Cyclosomatostatin
Catalog No.:BCC7693
CAS No.:84211-54-1
- Canagliflozin
Catalog No.:BCC3696
CAS No.:842133-18-0
- AKT Kinase Inhibitor
Catalog No.:BCC1335
CAS No.:842148-40-7
- Raclopride
Catalog No.:BCC7184
CAS No.:84225-95-6
- 5-O-Methylvisammioside
Catalog No.:BCN4954
CAS No.:84272-85-5
- Aliarin
Catalog No.:BCN3919
CAS No.:84294-77-9
- Pterosin D 3-O-glucoside
Catalog No.:BCN4567
CAS No.:84299-80-9
- 4,4'-Cyclohexylidenebisphenol
Catalog No.:BCC8663
CAS No.:843-55-0
The expression of sphingosine-1 phosphate receptor-1 in chronic lymphocytic leukemia cells is impaired by tumor microenvironmental signals and enhanced by piceatannol and R406.[Pubmed:25127862]
J Immunol. 2014 Sep 15;193(6):3165-74.
Chronic lymphocytic leukemia (CLL) is characterized by the progressive accumulation of clonal B lymphocytes. Proliferation occurs in lymphoid tissues upon interaction of leukemic cells with a supportive microenvironment. Therefore, the mobilization of tissue-resident CLL cells into the circulation is a useful therapeutic strategy to minimize the reservoir of tumor cells within survival niches. Because the exit of normal lymphocytes from lymphoid tissues depends on the presence of sphingosine-1 phosphate (S1P) and the regulated expression of S1P receptor-1 (S1PR1), we investigated whether the expression and function of S1PR1 can be modulated by key microenvironment signals. We found that activation of CLL cells with CXCL12, fibroblast CD40L(+), BCR cross-linking, or autologous nurse-like cells reduces their S1PR1 expression and the migratory response toward S1P. Moreover, we found that S1PR1 expression was reduced in the proliferative/activated subset of leukemic cells compared with the quiescent subset from the same patient. Similarly, bone marrow-resident CLL cells expressing high levels of the activation marker CD38 showed a lower expression of S1PR1 compared with CD38(low) counterparts. Finally, given that treatment with BCR-associated kinase inhibitors induces a transient redistribution of leukemic cells from lymphoid tissues to circulation, we studied the effect of the Syk inhibitors piceatannol and R406 on S1PR1 expression and function. We found that they enhance S1PR1 expression in CLL cells and their migratory response toward S1P. Based on our results, we suggest that the regulated expression of S1PR1 might modulate the egress of the leukemic clone from lymphoid tissues.
Pharmacokinetics and efficacy of the spleen tyrosine kinase inhibitor r406 after ocular delivery for retinoblastoma.[Pubmed:24906597]
Pharm Res. 2014 Nov;31(11):3060-72.
PURPOSE: Retinoblastoma is a childhood cancer of the retina. Clinical trials have shown that local delivery of broad spectrum chemotherapeutic agents is efficacious. Recent studies characterizing the genomic and epigenomic landscape of retinoblastoma identified spleen tyrosine kinase (SYK) as a promising candidate for targeted therapy. The purpose of this study was to conduct preclinical testing of the SYK antagonist R406 to evaluate it as a candidate for retinoblastoma treatment. METHODS: The efficacy of the SYK antagonist R406 delivered locally in a human orthotopic xenograft mouse model of retinoblastoma was tested. Intraocular exposure of R406 was determined for various routes and formulations. RESULTS: There was no evidence of efficacy for subconjunctival. R406. Maximal vitreal concentration was 10-fold lower than the minimal concentration required to kill retinoblastoma cells in vitro. Dosage of R406 subconjunctivally from emulsion or suspension formulations, direct intravitreal injection of the soluble prodrug of R406 (R788), and repeated topical administration of R406 all increased vitreal exposure, but failed to reach the exposure required for retinoblastoma cell death in culture. CONCLUSION: Taken together, these data suggest that R406 is not a viable clinical candidate for the treatment of retinoblastoma. This study highlights the importance of pharmacokinetic testing of molecular targeted retinoblastoma therapeutics.
In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib.[Pubmed:26516587]
Pharmacol Res Perspect. 2015 Oct;3(5):e00175.
Off-target pharmacology may contribute to both adverse and beneficial effects of a new drug. In vitro pharmacological profiling is often applied early in drug discovery; there are fewer reports addressing the relevance of broad profiles to clinical adverse effects. Here, we have characterized the pharmacological profile of the active metabolite of fostamatinib, R406, linking an understanding of drug selectivity to the increase in blood pressure observed in clinical studies. R406 was profiled in a broad range of in vitro assays to generate a comprehensive pharmacological profile and key targets were further investigated using functional and cellular assay systems. A combination of traditional literature searches and text-mining approaches established potential mechanistic links between the profile of R406 and clinical side effects. R406 was selective outside the kinase domain, with only antagonist activity at the adenosine A3 receptor in the range relevant to clinical effects. R406 was less selective in the kinase domain, having activity at many protein kinases at therapeutically relevant concentrations when tested in multiple in vitro systems. Systematic literature analyses identified KDR as the probable target underlying the blood pressure increase observed in patients. While the in vitro pharmacological profile of R406 suggests a lack of selectivity among kinases, a combination of classical searching and text-mining approaches rationalized the complex profile establishing linkage between off-target pharmacology and clinically observed effects. These results demonstrate the utility of in vitro pharmacological profiling for a compound in late-stage clinical development.
The kinase inhibitors R406 and GS-9973 impair T cell functions and macrophage-mediated anti-tumor activity of rituximab in chronic lymphocytic leukemia patients.[Pubmed:28011996]
Cancer Immunol Immunother. 2017 Apr;66(4):461-473.
Small molecules targeting kinases involved in B cell receptor signaling are showing encouraging clinical activity in chronic lymphocytic leukemia (CLL) patients. Fostamatinib (R406) and entospletinib (GS-9973) are ATP-competitive inhibitors designed to target spleen tyrosine kinase (Syk) that have shown clinical activity with acceptable toxicity in trials with CLL patients. Preclinical studies with these inhibitors in CLL have focused on their effect in patient-derived leukemic B cells. In this work we show that clinically relevant doses of R406 and GS-9973 impaired the activation and proliferation of T cells from CLL patients. This effect could not be ascribed to Syk-inhibition given that we show that T cells from CLL patients do not express Syk protein. Interestingly, zeta-chain-associated protein kinase (ZAP)-70 phosphorylation was diminished by both inhibitors upon TCR stimulation on T cells. In addition, we found that both agents reduced macrophage-mediated phagocytosis of rituximab-coated CLL cells. Overall, these results suggest that in CLL patients treated with R406 or GS-9973 T cell functions, as well as macrophage-mediated anti-tumor activity of rituximab, might be impaired. The potential consequences for CLL-treated patients are discussed.